Experimental Designs for Multicomponent Interventions in Kidney and Cardiometabolic Diseases.
作者信息
Rossing Peter
机构信息
Steno Diabetes Center Copenhagen, Herlev, Denmark; and Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.
出版信息
J Am Soc Nephrol. 2024 Oct 1;35(10):1438-1441. doi: 10.1681/ASN.0000000000000449. Epub 2024 Jul 5.
Abstract
摘要
相似文献
1
Experimental Designs for Multicomponent Interventions in Kidney and Cardiometabolic Diseases.肾脏和心脏代谢疾病多组分干预措施的实验设计
J Am Soc Nephrol. 2024 Oct 1;35(10):1438-1441. doi: 10.1681/ASN.0000000000000449. Epub 2024 Jul 5.
2
Vasopressin: novel roles for a new hormone - Emerging therapies in cardiometabolic and renal diseases.血管加压素：一种新激素的新作用——心血管代谢和肾脏疾病的新兴疗法
J Intern Med. 2017 Oct;282(4):281-283. doi: 10.1111/joim.12656.
3
Engagement With Conversational Agent-Enabled Interventions in Cardiometabolic Disease Management: Protocol for a Systematic Review.使用对话式代理进行的心血管代谢疾病管理干预措施的参与：系统评价的方案。
JMIR Res Protoc. 2024 Aug 7;13:e52973. doi: 10.2196/52973.
4
Gut microbiota and probiotics intervention: A potential therapeutic target for management of cardiometabolic disorders and chronic kidney disease?肠道微生物群和益生菌干预：管理心血管代谢疾病和慢性肾脏病的潜在治疗靶点？
Pharmacol Res. 2018 Apr;130:152-163. doi: 10.1016/j.phrs.2018.01.020. Epub 2018 Feb 14.
5
Candidate Interventions for Integrating Hypertension and Cardiovascular-Kidney-Metabolic Care in Primary Health Settings: HEARTS 2.0 Phase 1.在基层医疗卫生机构整合高血压与心血管-肾脏-代谢护理的候选干预措施：HEARTS 2.0 第一阶段
Glob Heart. 2025 May 27;20(1):45. doi: 10.5334/gh.1428. eCollection 2025.
6
Early referral strategies for management of people with markers of renal disease: a systematic review of the evidence of clinical effectiveness, cost-effectiveness and economic analysis.早期转介策略在管理有肾脏疾病标志物的人群中的应用：对临床有效性、成本效益和经济分析证据的系统评价。
Health Technol Assess. 2010 Apr;14(21):1-184. doi: 10.3310/hta14210.
7
Cardiovascular outcome trials in patients with chronic kidney disease: challenges associated with selection of patients and endpoints.慢性肾脏病患者的心血管结局试验：与患者选择和终点相关的挑战。
Eur Heart J. 2019 Mar 14;40(11):880-886. doi: 10.1093/eurheartj/ehx209.
8
Bone Marrow Niche in Cardiometabolic Disease: Mechanisms and Therapeutic Potential.心血管代谢疾病中的骨髓微环境：机制与治疗潜力
Circ Res. 2025 Jan 31;136(3):325-353. doi: 10.1161/CIRCRESAHA.124.323778. Epub 2025 Jan 30.
9
[Use of physical exercises in internal diseases].[体育锻炼在内科疾病中的应用]
Vopr Kurortol Fizioter Lech Fiz Kult. 1981 Nov-Dec(6):62-5.
10
The gut microbiome, diet, and links to cardiometabolic and chronic disorders.肠道微生物组、饮食与心血管代谢和慢性疾病的关联。
Nat Rev Nephrol. 2016 Mar;12(3):169-81. doi: 10.1038/nrneph.2015.191. Epub 2015 Nov 30.
本文引用的文献
1
Efficacy and safety of aldosterone synthase inhibition with and without empagliflozin for chronic kidney disease: a randomised, controlled, phase 2 trial.醛固酮合酶抑制联合和不联合恩格列净治疗慢性肾脏病的疗效和安全性：一项随机、对照、2 期临床试验。
Lancet. 2024 Jan 27;403(10424):379-390. doi: 10.1016/S0140-6736(23)02408-X. Epub 2023 Dec 15.
2
Diabetic Nephropathy: Update on Pillars of Therapy Slowing Progression.糖尿病肾病：治疗进展减缓支柱的最新进展。
Diabetes Care. 2023 Sep 1;46(9):1574-1586. doi: 10.2337/dci23-0030.
3
Fixed-Dose Combination Therapy for the Prevention of Cardiovascular Diseases in CKD: An Individual Participant Data Meta-Analysis.固定剂量联合治疗用于预防 CKD 患者的心血管疾病：一项个体参与者数据的荟萃分析。
Clin J Am Soc Nephrol. 2023 Nov 1;18(11):1408-1415. doi: 10.2215/CJN.0000000000000251. Epub 2023 Aug 8.
4
Optimization of Albuminuria-Lowering Treatment in Diabetes by Crossover Rotation to Four Different Drug Classes: A Randomized Crossover Trial.通过交叉轮换至四种不同药物类别优化糖尿病患者的蛋白尿降低治疗：一项随机交叉试验。
Diabetes Care. 2023 Mar 1;46(3):593-601. doi: 10.2337/dc22-1699.
5
Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): a multinational, open-label, randomised, trial.升阶梯治疗急性心力衰竭指南导向的药物治疗的安全性、耐受性和疗效（STRONG-HF）：一项多中心、开放标签、随机试验。
Lancet. 2022 Dec 3;400(10367):1938-1952. doi: 10.1016/S0140-6736(22)02076-1. Epub 2022 Nov 7.
6
Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes by Sodium-Glucose Cotransporter 2 Inhibitor Treatment: The FIDELITY Analysis.依格列净治疗的慢性肾脏病合并 2 型糖尿病患者的菲列净：FIDELITY 分析。
Diabetes Care. 2022 Dec 1;45(12):2991-2998. doi: 10.2337/dc22-0294.
7
Design of the COmbinatioN effect of FInerenone anD EmpaglifloziN in participants with chronic kidney disease and type 2 diabetes using a UACR Endpoint study (CONFIDENCE).使用 UACR 终点研究评估非奈利酮与恩格列净联用在慢性肾脏病合并 2 型糖尿病患者中的联合效应设计（CONFIDENCE）。
Nephrol Dial Transplant. 2023 Mar 31;38(4):894-903. doi: 10.1093/ndt/gfac198.
8
Albuminuria-Lowering Effect of Dapagliflozin, Eplerenone, and Their Combination in Patients with Chronic Kidney Disease: A Randomized Crossover Clinical Trial.达格列净、依普利酮及其联合应用对慢性肾脏病患者蛋白尿降低作用的随机交叉临床试验。
J Am Soc Nephrol. 2022 Aug;33(8):1569-1580. doi: 10.1681/ASN.2022020207. Epub 2022 Apr 19.
9
Years of life gained by multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: 21 years follow-up on the Steno-2 randomised trial.2型糖尿病合并微量白蛋白尿患者多因素干预所获寿命延长：斯滕诺-2随机试验21年随访
Diabetologia. 2016 Nov;59(11):2298-2307. doi: 10.1007/s00125-016-4065-6. Epub 2016 Aug 16.
10
Study rationale and design of ADVANCE: action in diabetes and vascular disease--preterax and diamicron MR controlled evaluation.ADVANCE研究的原理与设计：糖尿病和血管疾病中的行动——培哚普利吲达帕胺片与美吡达（格列吡嗪控释片）对照评估
Diabetologia. 2001 Sep;44(9):1118-20. doi: 10.1007/s001250100612.
Zotero 插件